MISSISSAUGA, Ontario, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its intentions to broaden its platform capabilities to enable production of a wider range of test ingredients (“Antigens”) by using recombinant production technologies. Directing existing in-house synthetic biology capabilities to this project will create large-scale recombinant Antigens production to complement and expand Micr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 MBX Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Delaware 001-42272 84-1882872 (Commission File Number) (IRS Employer Identification No.) 11711 N. Meridian Street Suite 300 Carmel, Indiana 46032 (Address of Principal Executive Offices) (Zip Code) FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a cli ...

Full-Year Revenues of $25.4 million and Net Income of $3.5 millionMISSISSAUGA, Canada, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2024 (“2024” and “Q4”) with record revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and that resulted in material net inc ...

Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform [3] - The company is advancing a pipeline of novel candidates targeting endocrine and metabolic disorders with clinically validated targets, established regulatory endpoints, significant unmet medical needs, and large market opportunities [3] - Key pipeline includes MBX 2109 (Phase 2 for chronic hypoparathyroidism), MBX 1416 (Phase 1 for post-bariatric hypoglycemia), and MBX 4291 (obesity portfolio) [3] Upcoming Events - The company's President and CEO, Kent Hawryluk, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 2:15 PM Pacific Time [1] - MBX Biosciences will participate in 1-on-1 investor meetings during the conference [1] - A live webcast of the presentation will be available on the company's investor website, with a replay accessible approximately two hours post-event and archived for 30 days [2]

CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of pos ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-----------------------------------------------------------------------------|-----------------------| | | | | For the transition period from _________________ to | _______ ...

Exhibit 99.1 MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be reported in early January 2025 Enrollment of Phase 2 Avail™ trial of MBX 2109 in hypoparathyroidism on track to complete in Q1 2025; topline results anticipated in Q3 2025 Strong cash posit ...